Astal Laboratories Ltd

Astal Laboratories Ltd has a liquidity position that is characterized by a current ratio of 1.7, indicating that the company has sufficient current assets to cover its current liabilities. However, the company's operating cash flow is negative at -125,173,000 INR, which may raise concerns about its ability to generate cash from operations. The company's free cash flow is positive at 33,734,000 INR, suggesting that it can fund operations and potentially invest in growth. In terms of profitability, the company's return on equity is 24.8%, which is a strong return relative to its equity base. The return on assets is 14.09%, indicating that the company is effectively using its assets to generate profit. The gross profit of 161,190,000 INR and operating income of 125,531,000 INR further support the company's profitability. Astal Laboratories Ltd operates in a single business segment focused on pharmaceutical intermediates and bulk drugs, with no disclosed geographic diversification beyond India. The company's revenue is concentrated in this segment, and there is no indication of significant geographic expansion or diversification. The company's growth trajectory is not explicitly detailed in the provided data, but the positive free cash flow and strong return on equity suggest potential for reinvestment and growth. The company's capital expenditure of -57,750,000 INR indicates that it is investing in its operations, which could support future growth. The risk assessment for Astal Laboratories Ltd indicates a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio of 0.37 suggests a relatively conservative capital structure. However, the negative net cash position after subtracting total debt may pose a liquidity challenge. Recent events and filings for Astal Laboratories Ltd are not detailed in the provided data, but the company's financial performance and risk profile suggest that it is maintaining a stable position in the pharmaceuticals industry.